Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MK-4482-009 | Other Identifier | MSD |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the study is to learn what happens to MK-4482 after single and multiple doses in healthy Chinese participants over time. Researchers also want to learn about the safety of MK-4482, including how well people tolerate it.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MK-4482 | Experimental | Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MK-4482 | Drug | Participants in period 1 received, MK-4482 800 mg single oral dose in the morning on Day 1. Participants in period 2 received, MK-4482 800mg oral dose administered every 12 hours (Q12H) on Day 1 through Day 6 for11 doses. |
| Measure | Description | Time Frame |
|---|---|---|
| The Maximum Observed Plasma Concentration (Cmax) After Single Oral Dose of MK-4482 in Period 1 | Cmax of N-hydroxycytidine (NHC) after a single oral dose of MK-4482 in period 1. | At designated time points up to 72 hours post-dose |
| Time to Reach Maximum Observed Plasma Concentration (Tmax ) After Single Oral Dose of MK-4482 in Period 1. | Tmax of NHC following single oral dose of MK-4482 in period 1. | At designated time points up to 72 hours post-dose |
| Elimination Half Life (T1/2) After Single Oral Dose of MK-4482 in Period 1 | T1/2 is defined as the time required for the concentration or amount of NHC in the body to be reduced by one-half after a single oral dose of MK-4482 in period 1. | At designated time points up to 72 hours post-dose |
| Apparent Total Clearance (CL/F) After Single Oral Dose of MK-4482 in Period 1 | CL/F of NHC from plasma after single oral dose of MK-4482 in period 1. | At designated time points up to 72 hours post-dose |
| Apparent Volume of Distribution (Vz/F) After Single Oral Dose of MK-4482 in Period 1 | Vz/F of NHC during terminal phase after single oral dose of MK-4482 in period 1. | At designated time points up to 72 hours post-dose |
| Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours Post-dose (AUC0-12hr) After Single Oral Dose of MK-4482 in Period 1 | This is a measure of the average amount of NHC in the plasma over a period of 12 hours after single oral dose of MK-4482 in period 1. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Who Experience an Adverse Event (AE) | An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported. | Up to ~ 5.5 weeks |
Not provided
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has a Body Mass Index (BMI) of 19 to 24 weight (kg)/height (m)2, inclusive, and body weight of ≥ 50 kg at the screening visit.
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Healthy male adult participants of Chinese descent
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Merck Sharp & Dohme LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking University Third Hospital (Site 0001) | Beijing | Beijing Municipality | 100191 | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41904711 | Result | Zhu J, Zhang D, Liu Z, Yan B, Zang Y, Zhao W, Sun F, Maas BM, Cheng MH, Stoch SA, Li H. Pharmacokinetics and Safety of Single and Multiple Doses of Molnupiravir in Healthy Male Chinese Adults: An Open-Label, Fixed Sequence, Phase 1 Study. Clin Transl Sci. 2026 Apr;19(4):e70481. doi: 10.1111/cts.70481. |
| Label | URL |
|---|---|
| Merck Clinical Trials Information | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000656703 | molnupiravir |
Not provided
Not provided
Not provided
Sequential model
Not provided
Not provided
Not provided
Not provided
| At designated time points up to 72 hours post-dose |
| Area Under the Plasma Concentration-time Curve From Time Zero to Last Measurable Concentration (AUC0-last) After Single Oral Dose of MK-4482 in Period 1 | AUC0-last of NHC following a single oral dose of MK-4482 in period 1. | At designated time points up to 72 hours post-dose |
| Area Under The Plasma Concentration Versus Time Curve From Time Zero (pre-dose) to Extrapolated Infinite Time (AUC0-inf) After Single Oral Dose of MK-4482 in Period 1 | AUC0-inf of NHC after single oral dose of MK-4482 in period 1. | At designated time points up to 72 hours post-dose |
| The Maximum Observed Plasma Concentration (Cmax) After Multiple Oral Doses of MK-4482 in Period 2 | Cmax of NHC after multiple oral doses of MK-4482 in period 2. | At designated time points up to 72 hours post-dose |
| Time to Reach Maximum Observed Plasma Concentration (Tmax ) After Multiple Oral Doses of MK-4482 in Period 2 | Tmax of NHC following multiple oral doses of MK-4482 in period 2. | At designated time points up to 72 hours post-dose |
| Elimination Half Life (T1/2) After Multiple Oral Doses of MK-4482 in Period 2 | T1/2 is defined as the time required for the concentration or amount of NHC in the body to be reduced by one-half after multiple oral doses of MK-4482 in period 2. | At designated time points up to 72 hours post-dose |
| Clearance at Steady State (CLss/F) After Multiple Oral Doses of MK-4482 in Period 2 | CLss/F of plasma NHC following multiple doses of MK-4482 in period 2. | At designated time points up to 72 hours post-dose |
| Apparent Volume of Distribution (Vz/F) After Multiple Oral Doses of MK-4482 in Period 2 | Vz/F of NHC during terminal phase after multiple doses of MK-4482 in period 2. | At designated time points up to 72 hours post-dose |
| Area Under the Plasma Concentration-time Curve From Time 0 to 12 Hours Post-dose (AUC0-12hr) After Multiple Oral Doses of MK-4482 in Period 2 | This is a measure of the average amount of NHC in the plasma over a period of 12 hours after multiple oral doses of MK-4482 in period 2. | At designated time points up to 72 hours post-dose |
| The Minimum Concentration (Ctrough) After Multiple Oral Doses of MK-4482 in Period 2 | Ctrough of NHC that occurred following multiple doses of MK-4482 in period 2. | At designated time points up to 72 hours post-dose |
| Accumulation Ratio on Cmax After Multiple Oral Doses of MK-4482 in Period 2 | The maximum concentration at steady state following multiple doses of MK-4482 in period 2 divided by the maximum concentration following the initial dosing in Period 1. | At designated time points up to 72 hours post-dose |
| Accumulation Ratio on AUC0-12hr After Multiple Oral Doses of MK-4482 | The AUC0-12hr at steady state following multiple doses of MK-4482 in period 2 divided by the AUC0-12hr following the initial dosing in Period 1. | At designated time points up to 72 hours post-dose |
| Number of Participants Who Discontinue Study Treatment Due to an AE |
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported. |
| Up to ~ 5.5 weeks |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |